Year: 2019
Type: review
Abstract: Decades of intense research in molecular biology and biochemistry are fructifying in the emergence of therapeutic messenger RNAs (mRNA) as a new class of drugs. Synthetic mRNAs can be sequence optimised to improve translatability into proteins, as well as chemically modified to reduce immunogenicity and increase chemical stability using naturally occurring uridine modifications. These structural improvements, together with the development of safe and efficient vehicles that preserve mRNA integrity in circulation and allow targeted intracellular delivery, have paved the way for mRNA-based therapeutics. Indeed, mRNAs formulated into biodegradable lipid nanoparticles are currently being tested in preclinical and clinical studies for multiple diseases including cancer immunotherapy and vaccination for infectious diseases. An emerging application of mRNAs is the supplementation of proteins that are not expressed or are not functional in a regulated and tissue-specific manner. This so-called 'protein replacement therapy' could represent a solution for genetic metabolic diseases currently lacking effective treatments. Here we summarise this new class of drugs and discuss the preclinical evidence supporting the potential of liver-mediated mRNA therapy for three rare genetic conditions: methylmalonic acidaemia, acute intermittent porphyria and ornithine transcarbamylase deficiency.
Source: Gut
Institutions: Instituto de Salud Carlos III, Navarre Institute of Health Research, Centro de Investigación Biomédica en Red de Cáncer, Centro de Investigación Médica Aplicada, Universidad de Navarra, Moderna Therapeutics (United States), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Awards: Explotando SR-B1 para el desarrollo de nuevos fármacos inmunomodulares para potenciar la inmunoterapia del cáncer, Ensayo preclínico del conjugado Apo AI con porfobilinógeno desaminasa para el tratamiento precoz de crisis agudas de porfiria. Validación de VDBP urinaria como biomarcador predictivo, Ensayo preclínico con ARN mensajero para el tratamiento etiológico de la porfiria aguda intermitente. Eficacia y seguridad en primates no humanos y en un nuevo modelo de porfiria hepática en conejo ., G7716198301
OpenAlex ID: W2917655435
